Moderna and Merck reported five-year follow-up results from their Phase IIb KEYNOTE-942/mRNA-4157-P201 study showing that intismeran autogene, Moderna’s personalized mRNA cancer vaccine, delivered a 49% reduction in the combined risk of melanoma recurrence or death when added to Merck’s anti-PD-1 therapy in patients with high-risk stage III/IV disease post-surgery. The hazard ratio of 0.51 remained consistent with the three-year analysis, underscoring the durability of the immune response. Safety outcomes were unchanged from earlier reports, with no new adverse events linked to the mRNA construct across the 600-patient cohort.

Following the plateau in its respiratory vaccine business, Moderna is accelerating investment in oncology, leveraging its nucleic acid platform to target multiple solid tumors. Intismeran autogene encodes up to 34 patient-specific neoantigens, triggering tailored T-cell responses. Beyond melanoma, Moderna and Merck have initiated Phase II and III trials in non-small cell lung, renal cell and bladder cancers. Moderna’s research pipeline now features eight late-stage oncology studies, reflecting a pivot that management forecasts could supply up to 40% of total revenue by 2030, based on internal modeling of peak vaccine uptake and pricing benchmarks set by existing immunotherapies.

Investor reaction was favorable, with Moderna’s share count-weighted performance up more than 15% the day of the announcement. Analysts cite the melanoma data as a potential harbinger for regulatory filing in 2027 and a launch in 2028, pending Phase III results. Jefferies projects peak global sales of $4 billion for intismeran autogene in melanoma alone, while Morgan Stanley forecasts an oncology franchise contribution of $10 billion by the end of the decade. Caution remains, however, as commercialization challenges include manufacturing scale-up of individualized vaccines and payer negotiation for six-figure dosing regimens.